https://www.bigpharmasharma.com/archivedailyhttps://www.bigpharmasharma.com/aboutweeklyhttps://www.bigpharmasharma.com/podcastweeklyhttps://www.bigpharmasharma.com/p/biogens-great-molt-is-complete2026-04-02monthlyhttps://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-march2026-03-30monthlyhttps://www.bigpharmasharma.com/p/reclaiming-the-narrative-what-biopharma2026-03-30monthlyhttps://www.bigpharmasharma.com/p/whos-actually-earning-their-seat2026-03-11monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-9-using-ai-to-find2026-02-26monthlyhttps://www.bigpharmasharma.com/p/why-gilead-really-bought-arcellx2026-02-24monthlyhttps://www.bigpharmasharma.com/p/the-fda-decision-that-just-setback2026-02-13monthlyhttps://www.bigpharmasharma.com/p/consulting-and-advisory-work2026-02-01monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-8-2026-predictions2026-01-29monthlyhttps://www.bigpharmasharma.com/p/big-pharma-at-jpm-2026-m-and-a-obesity2026-01-29monthlyhttps://www.bigpharmasharma.com/p/six-biotechs-getting-acquired-in2026-01-29monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-podcast-archive2026-01-29monthlyhttps://www.bigpharmasharma.com/p/ash-2025-is-this-the-beginning-of2025-12-10monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-7-biotech-m-and-a2025-11-20monthlyhttps://www.bigpharmasharma.com/p/is-cell-therapy-out-of-favor-or-undervalued2025-12-16monthlyhttps://www.bigpharmasharma.com/p/caribou-whispers-parity-with-vispa2025-11-04monthlyhttps://www.bigpharmasharma.com/p/genmabs-halloween-costume-and-nk2025-10-04monthlyhttps://www.bigpharmasharma.com/p/pfizer-acquires-a-glp-1-pipeline2025-09-25monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-podcast-ep-6-should-the2025-09-09monthlyhttps://www.bigpharmasharma.com/p/the-in-vivo-gold-rush-big-pharmas2025-10-10monthlyhttps://www.bigpharmasharma.com/p/modernas-oncology-inflection-point2025-08-05monthlyhttps://www.bigpharmasharma.com/p/changing-of-the-guard-at-abbvie-new2025-07-16monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-5-how-to-talk-to-doctors2025-07-01monthlyhttps://www.bigpharmasharma.com/p/asco-2025-final-round-up-of-analyses2025-06-18monthlyhttps://www.bigpharmasharma.com/p/asco-2025-bicara-vs-merus-in-a-set2025-06-09monthlyhttps://www.bigpharmasharma.com/p/asco25-ivonescimab-dis-harmoni-is2025-06-02monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep4-ozempic-for-the-brain2025-05-19monthlyhttps://www.bigpharmasharma.com/p/vinay-prasad-at-cber-what-his-appointment2025-05-09monthlyhttps://www.bigpharmasharma.com/p/what-2025-holds-for-glp-1s-in-brain2025-07-23monthlyhttps://www.bigpharmasharma.com/p/biotech-czar-for-a-day-an-abundance2025-03-31monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-3-rise-of-the-phoenix2025-03-10monthlyhttps://www.bigpharmasharma.com/p/the-unraveling-of-hims-glp-1-strategy2025-03-03monthlyhttps://www.bigpharmasharma.com/p/a-crucial-moment-in-ipf-what-boehringer2025-02-19monthlyhttps://www.bigpharmasharma.com/p/when-the-placebo-winsand-sometimes2025-02-07monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-2-predictions-for2025-01-31monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-1-do-pharma-companies2025-01-31monthlyhttps://www.bigpharmasharma.com/p/drug-dealin-ep-0-welcome-to-the-drug2025-01-31monthlyhttps://www.bigpharmasharma.com/p/biotech-at-a-crossroads-insights2025-01-22monthlyhttps://www.bigpharmasharma.com/p/galapagos-hits-reset-with-spinout2025-01-09monthlyhttps://www.bigpharmasharma.com/p/looking-into-the-crystal-ball-five2024-12-29monthlyhttps://www.bigpharmasharma.com/p/ash-part-2-anito-cel-is-off-to-the2024-12-11monthlyhttps://www.bigpharmasharma.com/p/ash-2024-part-1-miltenyi-and-galapagos2024-12-09monthlyhttps://www.bigpharmasharma.com/p/free-posts-starter-pack2025-01-10monthlyhttps://www.bigpharmasharma.com/p/two-things-i-think-coming-out-of2024-11-20monthlyhttps://www.bigpharmasharma.com/p/flipping-the-script-on-failed-immuno2024-10-28monthlyhttps://www.bigpharmasharma.com/p/priority-review-voucher-prv-market2024-11-04monthlyhttps://www.bigpharmasharma.com/p/tigit-too-legit-to-quit-or-just-cant2024-10-07monthlyhttps://www.bigpharmasharma.com/p/three-major-implications-coming-out2024-09-20monthlyhttps://www.bigpharmasharma.com/p/what-the-ivonescimab-data-at-wclc2024-09-23monthlyhttps://www.bigpharmasharma.com/p/two-charts-that-highlight-the-future2024-09-02monthlyhttps://www.bigpharmasharma.com/p/rethinking-the-fda-innovation-and2024-09-20monthlyhttps://www.bigpharmasharma.com/p/why-you-should-be-paying-attention2025-06-02monthlyhttps://www.bigpharmasharma.com/p/esmo-2024-my-most-interesting-abstracts2024-09-06monthlyhttps://www.bigpharmasharma.com/p/what-the-artiva-ipo-says-about-the2024-07-22monthlyhttps://www.bigpharmasharma.com/p/safety-signals-in-lyells-ror-1-car2024-07-01monthlyhttps://www.bigpharmasharma.com/p/can-roches-columvi-threaten-the-car2025-05-20monthlyhttps://www.bigpharmasharma.com/p/asco-2024-temperature-check-part-03d2024-06-17monthlyhttps://www.bigpharmasharma.com/p/asco-2024-temperature-check-part2024-06-10monthlyhttps://www.bigpharmasharma.com/p/mini-asco-2024-preview-an-emerging2024-05-30monthlyhttps://www.bigpharmasharma.com/p/the-renaissance-of-psychedelics-charting2024-05-21monthlyhttps://www.bigpharmasharma.com/p/asco-2024-most-interesting-data-upcoming2024-05-30monthlyhttps://www.bigpharmasharma.com/p/cd19-bispecifics-the-harbinger-of2024-04-25monthlyhttps://www.bigpharmasharma.com/p/some-signs-of-life-for-new-il-2-variants2024-04-15monthlyhttps://www.bigpharmasharma.com/p/deconstructing-granites-downfall2024-09-20monthlyhttps://www.bigpharmasharma.com/p/bayers-renaissance-a-roadmap-for2024-03-26monthlyhttps://www.bigpharmasharma.com/p/what-the-bcma-car-t-adcom-revealed2024-03-18monthlyhttps://www.bigpharmasharma.com/p/aacr-2024-most-interesting-abstract2024-03-11monthlyhttps://www.bigpharmasharma.com/p/updated-cell-therapy-autoimmune-landscape2024-03-04monthlyhttps://www.bigpharmasharma.com/p/a-til-ing-odyssey-finally-ends-in2026-02-23monthlyhttps://www.bigpharmasharma.com/p/an-interview-with-ai-about-its-role2024-02-18monthlyhttps://www.bigpharmasharma.com/p/a-few-charts-that-outline-the-dearth2024-09-20monthlyhttps://www.bigpharmasharma.com/p/quick-takes-overreacting-to-recent2024-02-07monthlyhttps://www.bigpharmasharma.com/p/the-next-phase-how-biontech-and-moderna2024-01-23monthlyhttps://www.bigpharmasharma.com/p/sponsored-posts2025-12-12monthlyhttps://www.bigpharmasharma.com/p/on-the-ground-at-jpm-key-themes-that2024-01-15monthlyhttps://www.bigpharmasharma.com/p/astrazenecas-build-towards-becoming2024-01-05monthlyhttps://www.bigpharmasharma.com/p/five-lists-of-five-an-end-of-20232023-12-22monthlyhttps://www.bigpharmasharma.com/p/ash-2023-zeitgeist-review-winners2023-12-14monthlyhttps://www.bigpharmasharma.com/p/quick-takes-implications-from-a-few2024-02-07monthlyhttps://www.bigpharmasharma.com/p/everybody-is-in-cell-therapy-now2023-11-30monthlyhttps://www.bigpharmasharma.com/p/cell-therapy-for-type-1-diabetes2023-11-22monthlyhttps://www.bigpharmasharma.com/p/diving-into-the-clinical-immune-cell2023-11-16monthlyhttps://www.bigpharmasharma.com/p/ash-2023-non-lba-most-interesting2023-11-13monthlyhttps://www.bigpharmasharma.com/p/my-three-big-winners-from-esmo2023-11-03monthlyhttps://www.bigpharmasharma.com/p/esmo-2023-biontechs-cell-therapy2023-10-27monthlyhttps://www.bigpharmasharma.com/p/analyzing-bms-acquisition-of-mirati2023-10-11monthlyhttps://www.bigpharmasharma.com/p/esmo-2023-most-interesting-late-breaking2023-10-07monthlyhttps://www.bigpharmasharma.com/p/quick-takes-a-handful-of-charts-on2024-02-07monthlyhttps://www.bigpharmasharma.com/p/quick-takes-double-clicking-into2024-02-07monthlyhttps://www.bigpharmasharma.com/p/esmo-2023-my-most-interesting-abstracts2023-09-16monthlyhttps://www.bigpharmasharma.com/p/document-library-for-proindustry2023-11-22monthlyhttps://www.bigpharmasharma.com/p/quick-take-tivdaks-positive-innovatv2024-02-07monthlyhttps://www.bigpharmasharma.com/p/quick-take-imbruvicas-decline-ira2024-02-07monthlyhttps://www.bigpharmasharma.com/p/bbt-replimune-repl-looking-to-restore2023-08-24monthlyhttps://www.bigpharmasharma.com/p/about-big-pharma-sharma2023-09-14monthlyhttps://www.bigpharmasharma.com/p/biopharma-buyout-targets-bbt-immunogen2023-08-21monthlyhttps://www.bigpharmasharma.com/p/big-pharma-sharma-pricing-model2025-09-16monthlyhttps://www.bigpharmasharma.com/p/big-pharma-learnings-q223-gilead2023-09-14monthlyhttps://www.bigpharmasharma.com/p/big-pharma-learnings-q223-bms-abbvie2023-09-14monthlyhttps://www.bigpharmasharma.com/p/q223-big-pharma-learnings-season2023-09-14monthlyhttps://www.bigpharmasharma.com/p/the-limited-speed-of-fast-cars2023-09-14monthlyhttps://www.bigpharmasharma.com/p/priority-review-voucher-prv-database2023-09-14monthlyhttps://www.bigpharmasharma.com/p/amazon-should-buy-a-generic-drug2024-09-20monthlyhttps://www.bigpharmasharma.com/p/ascoehaicml-2023-look-back-car-t2023-09-14monthlyhttps://www.bigpharmasharma.com/p/an-intro-to-big-pharma-sharma2023-09-14monthly